Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors
At American Association for Cancer Research Annual Meeting 2022 New Orleans, April 8 13 Regulatory News: OSE Immunotherapeutics (Paris:OSE)(ISIN: FR0012127173; Mnemo: OSE), today announced that
United States New Orleans New Orleans Convention Center Guillaume Van Renterghem Lifesci Thomas Guillot Florence Portejoie
Source: finanznachrichten.de